EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Reprint Email

TheStreet Wire

Dow Today: Pfizer (PFE) Higher

By TheStreet Wire 08/01/12 - 01:00 PM EDT

Find out if (PFE) is in Cramer's Portfolio.

The Dow Jones Industrial Average (^DJI) is trading up 36 points (+0.3%) at 13,044 as of Wednesday, Aug 1, 2012, 12:35 p.m. ET. During this time, 243.6 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 690.1 million. The NYSE advances/declines ratio sits at 1,685 issues advancing vs. 1,218 declining with 135 unchanged.

ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

The Dow component leading the way higher looks to be Pfizer (NYSE:PFE), which is sporting a 24-cent gain (+1%) bringing the stock to $24.06. This single gain is lifting the Dow Jones Industrial Average by 1.82 points or roughly accounting for 5.1% of the Dow's overall gain. Volume for Pfizer currently sits at 22.9 million shares traded vs. an average daily trading volume of 35.2 million shares.

Pfizer has a market cap of $177.54 billion and is part of the health care sector and drugs industry. Shares are up 9.6% year to date as of Tuesday's close. The stock's dividend yield sits at 3.7%.

Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. The company has a P/E ratio of 22.2, above the average drugs industry P/E ratio of 19 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

You can view the full Pfizer Ratings Report.

For more information on Pfizer Inc click any of the following:

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:

$2.5+ million portfolio
Large-cap and dividend focus
Intraday trade alerts from Cramer
Weekly roundups

Dividend Stock Advisor

TRY IT FREE

New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:

Diversified model portfolio of dividend stocks
Alerts when market news affect the portfolio
Bi-weekly updates with exact steps to take - BUY, HOLD, SELL

Stocks Under $10

TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:

Model portfolio
Stocks trading below $10
Intraday trade alerts
Weekly roundups

Real Money

TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:

Jim Cramer + 20 Wall Street pros
Intraday commentary & news
Real-time trading forum
Actionable trade ideas

Real Money Pro

TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:

Real Money + Doug Kass + 15 more Wall Street Pros
Intraday commentary & news
Ultra-actionable trading ideas

Options Profits

TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.